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Abstract
An increased prevalence of various filamentous fungi in sputum samples of patients with cystic fibrosis
(CF) has been reported. The clinical significance, however, is mostly unclear. The aim of this study was to
investigate the clinical relevance of Scedosporium spp. and Exophiala dermatitidis from sputum samples of
patients with CF in the Netherlands. In this cross-sectional study, all CF patients of the Dutch national CF reg-
istry who were treated at five of the seven recognized CF centers during a 3-year period were included. We
linked clinical data of the national CF registry with the national Dutch filamentous fungal database. We inves-
tigated the association between clinical characteristics and a positive sputum sample for Scedosporium spp.
and E. dermatitidis, using logistic regression. Positive cultures for fungi were obtained from 3787 sputum
samples from 699 of the 1312 patients with CF. Scedosporium spp. was associated with severe genotype, CF-
related diabetes, several microorganisms, and inhaled antibiotics. E. dermatitidis was associated with older
age, female sex, and Aspergillus spp. CF patients with and without Scedosporium spp. or E. dermatitidis
seemed comparable in body mass index and lung function. This study suggests that Scedosporium spp.
and E. dermatitidis are probably no major pathogens in CF patients in the Netherlands. Greater understand-
ing of epidemiologic trends, risk factors, and pathogenicity of filamentous fungi in the respiratory tracts of
patients with CF is needed.
Key words: cystic fibrosis, filamentous fungi, Scedosporium, Exophiala, epidemiology.
Introduction
Cystic fibrosis (CF) is the most common lethal autosomal re-
cessive disease among populations with northern European
ancestry.1 It is a multiorgan disorder and mostly affects the
lungs. Progressive chronic lung inflammation and infection is re-
sponsible for at least 80% of CF-related deaths.1,2 The main
cause of chronic lung inflammation and infection are bac-
teria, such as Staphylococcus aureus, Burkholderia cepacia,
Stenotrophomonas maltophilia, and Pseudomonas aeruginosa.2
In addition to bacteria, filamentous fungi are increasingly recov-
ered in respiratory cultures from patients with CF.3–5 Aspergillus
fumigatus is the fungus most frequently cultured in patients with
CF. Reported prevalence rates based on sputum cultures vary
from 16% to 57% in CF patients.3–8 It has been associated
with allergic bronchopulmonary aspergillosis (ABPA), hospital-
ization, and lung function decline.7 Scedosporium species have
been reported as the second most prevalent filamentous fungus
isolated in sputa from 2 to 9% of the patients with CF.3,5,9,10
Its isolation has been associated with older age, white race, and
inhaled antibiotic use.10,11 The genus Scedosporium is an ubiq-
uitous filamentous fungus present mainly in soil, sewage, and
polluted waters.12 Several species of Scedosporium have been re-
ported in CF: Scedosporium apiospermum, Scedosporium boy-
dii, Lomentospora prolificans and Scedosporium aurantiacum,
Scedosporium ellipsoideum, Scedosporiumminutisporum.13 The
black yeast Exophiala dermatitidis is able to grow as a filamen-
tous fungus in humid environments such as dishwashers and
steam baths14 and has been isolated from a significant percentage
(1–16%) of CF patients.6,13,15
The clinical relevance of these two filamentous fungi is un-
clear, leading to a lack of guidelines for clinical management.16
Besides A. fumigatus, other filamentous fungi are increasingly
reported as well, although mostly in small numbers and in sin-
gle center studies.13,15,17 Whether presence of Scedosporium spp.
and E. dermatitidis in the lungs only causes harmless coloniza-
tion of the airways, or also constitutes a clinically relevant risk
for patients with CF remains a matter of debate.10,16,18,19
The aim of this study was to investigate the clinical relevance
of Scedosporium spp. and E. dermatitidis from sputum samples




In this cross-sectional study, all CF patients of the Dutch na-
tional CF registry who were treated at five of the seven rec-
ognized CF centers between March 22, 2010, and March 27,
2013 were included. Patients with a history of lung transplanta-
tion were excluded. We linked the national CF registry with the
Dutch CF Fungal Collection Consortium (DCFFCC). Data were
pseudonymized prior to analysis. Formal approval from the in-
stitutional review board was waived.
National CF registry
The national CF registry was established to support scientific re-
search and improve CF care and treatment.20 It covers 98% of
all patients with CF in the Netherlands. The five included centers
represent 82% of the patients. The diagnosis of CF disease was
based on typical clinical features associated with a positive sweat
test (chloride >60 mmol/l) and/or the presence of two known









y/article/58/7/859/5728812 by guest on 26 February 2021
de Jong et al. 861
Clinical characteristics
The following parameters were retrieved from the national CF
registry: age, sex, body mass index (BMI), CFTR mutation, CF-
related diabetes (CFRD), allergic bronchopulmonary aspergillo-
sis (ABPA), lung function (forced expiratory volume in 1 sec-
ond (FEV1) % predicted), presence of positive sputum sample(s)
for Pseudomonas aeruginosa, Stenotrophomonas maltophilia,
Staphylococcus aureus, Burkholderia cepacia, nontuberculous
mycobacteria, and Aspergillus spp., use of inhaled or oral cor-
ticosteroids, azithromycin or inhalation antibiotics, and history
of lung transplantation. FEV1 was measured at least 4 times a
year during routine visits, and the highest value per year was
recorded. A patient receiving daily insulin during at least 1 year
of the research period was classified as having CFRD. Continu-
ous inhaled antibiotics or oral azithromycin use was defined as
use for more than 3 months during at least 1 year. Sputum cul-
tures of the year 2010 and 2011 were linked to clinical data from
the national CF registry of the year 2011, and sputum cultures
of the year 2012 and 2013 were linked to clinical data from the
national CF registry of the year 2012.
Dutch CF fungal collection consortium
The DCFFCC was established to study the epidemiology, micro-
biological characteristics, and clinical relevance of fungal infec-
tion and colonization among patients with CF in the Nether-
lands. For this aim, we collected all sputum cultures positive for
filamentous fungi from patients with CF who were treated at the
five participating CF centers in the Netherlands between March
22, 2010, and March 27, 2013. At the local hospital, sputum
samples were collected and examined for fungi 4 times a year
during routine visits and during hospitalization. Therefore, we
considered patients of whom we did not receive a sputum cul-
ture as negative. Measurement bias was avoided by excluding
the two centers who participated only partially and did not send
all positive sputum samples and by using one reference lab for
molecular identification.
Fungal culture media and methods
Details on the fungal culture media and methods were pre-
viously published.13 Briefly, agar plates were provided to the
participating laboratories from a central location. Every week,
batches of filamentous fungi, recovered at the participating
laboratories, were transported to a central microbiology labora-
tory of Canisius Wilhelmina Hospital Nijmegen on the original
plates. Samples were inoculated onto Sabouraud dextrose agar
(SDA, Oxoid, Basingstoke, UK) and medium B+ agar plates.21
All inoculated plates were incubated aerobically at 30°C for
3 weeks and checked for growth daily in the first week and
twice per week in the second and third week. The reference
laboratory identified the isolates with internal transcribed spacer
sequencing and registered the fungus in the DCFFCC database.22
Statistical analyses
We compared patients with a positive sputum sample with pa-
tients without a positive sputum sample for Scedosporium spp.
and Exophiala dermatitidis, using χ2, Fisher exact, and t tests.
We investigated the association between clinical characteristics
and a positive sputum sample for Scedosporium spp. and Ex-
ophiala dermatitidis using logistic regression analysis with ad-
justment for sex and age. We did a sensitivity analysis compar-
ing patients with more than one positive sputum sample with
patients without a positive sputum sample.We used STATA soft-
ware (version 14; College Station, TX, USA) for all analysis.
Results
During the study period, 699 (53%) of the 1312 patients with
CF had at least one positive sputum sample. In total, 3787 sam-
ples containing fungal isolates were obtained. A large variety of
107 species of filamentous fungi was encountered in CF patients.
The median age was 21 years (range 0–72). The median number
of positive sputum samples per patient in this study was three
(range 1–35).
Scedosporium spp. were recovered from 94 (7%) of the 1312
patients with CF and from 225 sputum samples (6%) during the
research period (Table 1). The mean age of these 94 patients was
22 years (range 0–56), and the majority was female and had two
severe CFTR mutations (class I–III) (Table 2). The median num-
ber of sputum samples per patient with Scedosporium spp. was
11 (range 1–35).
The clinical characteristics of patients with CF and at least
one positive sputum sample of Scedosporium spp. compared
to those without a positive sputum sample with Scedosporium
spp. are shown in Figure 1. The two groups were comparable
with respect to age and inhaled corticosteroid use. Severe geno-
type (odds ratio 2.86, 95% confidence interval [CI] 1.42–5.76),
CF-related diabetes (1.80, 1.10–2.95), use of inhaled antibiotics
(1.60, 1.03–2.48), and coinfection with Stenotrophomonas mal-
tophilia (2.47, 1.37–4.45), Staphylococcus aureus (1.81, 1.17–
2.79), and Aspergillus spp. (2.77, 1.77–4.32) were associated
with Scedosporium spp. CF patients with or without Scedospo-
rium spp. had almost a similar mean BMI (1.03, 0.96–1.11) and
FEV1% predicted (1.00, 0.99–1.01), also when adjusted for age
and sex.
Exophiala dermatitidis was cultured from 57 (2%) sputum
samples of 31 (2%) of the 699 patients with CF (Table 1). The
mean age of the 31 CF patients with Exophiala dermatitidis was
28 years (range 10–59), and the majority was female (Table 3).
The median number of sputum samples with Exophiala dermati-
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Table 1. Isolation rate of Scedosporium spp. and Exophiala dermatitides.
Patients with CFa N = 1312 Positive sputum samples N = 3787
n (%) n (%)
Total Scedosporium spp. 94 (7) 225 (6)
Scedosporium apiospermum 23 (2) 66 (2)
Scedosporium boydii 16 (1) 55 (2)
Scedosporium ellipsoideum 11 (1) 27 (1)
Scedosporium aurantiacum 11 (1) 19 (1)
Lomentospora prolificans 4 (<1) 8 (<1)
Scedosporium minutisporum 1 (<1) 1 (<1)
Scedosporium spp. – no species identification 45 (3) 49 (1)
Exophiala dermatitidis 31 (2) 57 (2)
aCystic fibrosis.
Table 2. Clinical characteristics of patients with Scedosporium spp. positive and negative sputum samples.
Scedosporium spp. positive N = 94 Scedosporium spp. negative N = 1218
n (%) n (%) P-valuea
Demographic factors
Age, years (mean, SD) 22 (12) 21 (15) 0.345
Sex, female 53 (56) 575 (47) 0.088
BMI, (mean, SD) 20 (3) 20 (4) 0.173
Genotype, severe CFTR mutationsb 83 (89) 949 (78) 0.010
Disease characteristics
CF-related diabetes 30 (33) 232 (20) 0.003
ABPA 14 (15) 105 (9) 0.049
Lung function, FEV1 (mean, SD) 71 (23) 71 (25) 0.950
Microorganisms
Pseudomonas aeruginosa 43 (47) 387 (35) 0.020
Stenotrophomonas maltophilia 16 (17) 85 (8) 0.001
Staphylococcus aureus 43 (47) 369 (33) 0.007
Burkholderia cepacia 2 (2) 21 (2) 0.692
Nontuberculous mycobacteria 3 (3) 15 (1) 0.150
Aspergillus spp. 47 (51) 283 (26) <0.001
Medications
Inhalation corticosteroids 32 (36) 315 (31) 0.370
Azithromycin 50 (56) 485 (46) 0.071
Inhalation antibiotics 48 (52) 447 (39) 0.012
aT-test for continuous variables, Chi-2 for binary variables and Fisher’s exact for binary variables with less than 10 cases.
bSevere mutations was defined as 2 CFTR mutations from class I-III.
ABPA, allergic bronchopulmonary aspergillosis; BMI, body mass index; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; FEV1,. forced expiratory
volume in 1 second.
CF patients with Exophiala dermatitidis had more severe
genotypes after adjusting for age and sex (3.31, 1.08–10.12),
were slightly older (1.03, 1.01–1.06) and were mostly female
(2.45, 1.14–5.26) (Fig. 2). Aspergillus spp. coinfection (2.12,
1.01–4.45) was more frequently observed in CF patients with
Exophiala dermatitidis than in those without (Fig. 2). The fre-
quency of co-infections with bacteria, use of medication did
not differ between the two groups. CF patients with Exophiala
dermatitidis had a weak association with the BMI compared
to those without Exophiala dermatitidis, however, after ad-
justment for age and sex, BMI and FEV1% predicted were
similar in both groups (1.09, 0.98–1.22 and 0.99, 0.98–1.01,
respectively).
Our sensitivity analysis showed similar results in patients
with more than one positive sputum sample for Scedosporium
spp. (Table S1, and Fig. S1). CF patients with and without Sce-
dosporium spp. had comparable BMI (1.06, 0.96–1.18) and
FEV1% predicted (1.00–0.98–1.01). The number of patients
with more than one positive sputum sample for Exophiala der-
matitidiswere too small to do logistic regression, but the compar-
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Figure 1. Clinical factors associated with Scedosporium species, odds ratio’s unadjusted (red dot) and adjusted for age and sex (blue cross) (N = 1312). ABPA,
allergic bronchopulmonary aspergillosi; BMI, body mass index; CFRD,cystic fibrosis related diabetes; FEV1, forced expiratory volume in 1 second. This Figure is
reproduced in color in the online version ofMedical Mycology.
Table 3. Clinical characteristics of patients with Exophiala dermatitidis positive and negative sputum samples.
Exophiala dermatitidis positive N = 31 Exophiala dermatitidis negative N = 1281
n (%) n (%) P-valueb
Demographic factors
Age, years (mean, SD) 28 (13) 21 (14) 0.005
Sex, female 21 (68) 607 (47) 0.025
BMI, (mean, SD) 22 (3) 20 (4) 0.003
Genotype, severe CFTR mutationsa 27 (87) 1005 (78) 0.246
Disease characteristics
CF-related diabetes 6 (19) 256 (21) 1.000
ABPA 4 (13) 116 (9) 0.529
Lung function, FEV1 (mean, SD) 65 (19) 71 (25) 0.167
Microorganisms
Pseudomonas aeruginosa 11 (37) 420 (36) 0.950
Stenotrophomonas maltophilia 3 (10) 98 (8) 0.733
Staphylococcus aureus 10 (33) 404 (34) 0.926
Burkholderia cepacia 1 (3) 22 (2) 0.442
Non-tuberculous mycobacteria 1 (3) 17 (1) 0.364
Aspergillus spp. 15 (50) 314 (27) 0.005
Medications
Inhalation corticosteroids 15 (48) 330 (31) 0.044
Azithromycin 18 (58) 512 (47) 0.208
Inhalation antibiotics 14 (45) 483 (40) 0.551
aSevere mutations was defined as 2 CFTR mutations from class I-III.
bT-test for continuous variables, Chi-2 for binary variables and Fisher’s exact for binary variables with less than 10 cases.
BMI: bodymass index,CFTR: Cystic fibrosis transmembrane conductance regulator, CF: Cystic fibrosis, ABPA: allergic bronchopulmonary aspergillosis, FEV1: forced expiratory
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Figure 2. Clinical factors associated with Exophiala dermatitidis, odds ratio’s unadjusted (red dot) and adjusted for age and sex (blue cross) (N = 1312). ABPA,
allergic bronchopulmonary aspergillosis; BMI, body mass index; CFRD, cystic fibrosis related diabetes; FEV1, forced expiratory volume in 1 second. This Figure
is reproduced in color in the online version ofMedical Mycology.
Discussion
We describe the clinical relevance of two species of non-
Aspergillus filamentous fungi in a national cohort of Dutch CF
patients. Our results showed that CF patients with and with-
out Scedosporium spp. or Exophiala dermatitidis were compa-
rable with regard to BMI and lung function. Scedosporium spp.
was associated with severe genotype, CF-related diabetes, several
microorganisms, and inhaled antibiotics.Exophiala dermatitidis
was associated with older age, female sex, severe genotype, and
Aspergillus spp.
Only one other multicenter study determined clinical fac-
tors associated with Scedosporium spp. isolation in patients
with CF.10 This American retrospective cohort study found that
FEV1% predicted was not associated with Scedosporium spp.
isolation (odds ratio 0.99, 95% CI 0.96–1.04), which is in line
with our findings (1.00, 0.99–1.01).10 An Australian single cen-
tre study did not find a difference in FEV1 between patients with
and without Scedosporium spp. either.17 In the study by Hong
et al., higher BMI was associated with lower probability of Sce-
dosporium spp. in adults (0.90, 0.87–0.91) but not in children
(0.96, 0.91–1.01). In comparison, we did not find a difference in
BMI in our age-adjusted model (1.03, 0.96–1.11).
Our finding that inhaled antibiotic treatment was associated
with positive sputum cultures for Scedosporium spp. (1.60, 1.03–
2.48) is in line with findings by Hong et al. (2.01, 1.61–2.52)
and Blyth et al.10,17 Both previous studies also found this asso-
ciation with other fungi such as Aspergillus, suggesting that the
widespread use of broad-spectrum antibiotics has favored the se-
lection and opportunities of growth and colonization of fungi in
the respiratory tract.5
Blyth et al. and Kaur et al. both suggested that Scedospo-
rium colonization/infection occurs less frequently in patients col-
onized by mucoid Pseudomonas aeruginosa.17,23 In contrast,
we found an indication that Pseudomonas aeruginosa occurred
more frequently in patients with a positive sputum culture for
Scedosporium spp. which is in line with Hong et al.10 Synergistic
or antagonistic interactions within the polymicrobial flora colo-
nizing the airways in CF patients have been described, especially
for Aspergillus fumigatus.7 An association between fungi, col-
onizing bacteria, and antimicrobial use has been observed for
Aspergillus fumigatus, with increased risk for colonization of
Aspergillus in combination with Pseudomonas aeruginosa and
Burkholderia cepacia.7 The association of Burkholderia cepa-
cia co-colonization was not found in our study for Scedospo-
rium spp. due to very few Burkholderia cepacia co-colonizations,
which is in line with Hong et al.10 We found an association
between the presence of Stenotrophomonas maltophilia and a
positive sputum sample for Scedosporium spp., which has also
been found with Aspergillus fumigatus in a French single center
study.3
Exophiala dermatitidis has been studied less, which could be
due to the fact that routine isolation techniques are insufficient
to detect this slow growing fungus in specimens from CF pa-
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4 weeks).6 Lebecque et al. did not find any associations between
treatment with continuous antibiotic treatment and colonization
with Exophiala dermatitidis and neither did we.15
It was also suggested that A. fumigatus coinfection is asso-
ciated with an increased risk of Exophiala dermatitidis and that
Pseudomonas aeruginosa is less frequently found in patients with
Exophiala dermatitidis.15,24 In our study, a slight indication was
found for the latter. A possible explanation could be that Pseu-
domonas aeruginosa has been reported to inhibit fungal growth
by certain extracts from the extracellular mucus.6
A strength of this study is that it utilizes data of a large CF co-
hort followed for 3 years.Many other studies of fungal infection
in CF patients have been limited by small sample size, short study
time, or lack of correlating clinical details. Using data from a
multicenter study improves the external validity of the study.Due
to the reference laboratory, uniformity in the culturing, molecu-
lar typing and detection of filamentous fungi was assured.
One limitation of the study is that we did not use a
Scedosporium-selective medium, such as the Scesel + medium,
which might have led to an underestimation of the Scedosporium
spp. positive sputum samples.25,26 In our study, we used medium
B+, which has better bacterial inhibition than the routinely used
Sabouraud followed by polymerase chain reaction based identi-
fication. We did not have clinical data from the national CF reg-
istry for the whole study period. Therefore, we used clinical data
from 2011 and 2012 as a proxy.This could have let tomisclassifi-
cation bias. In patients with CF, the lung function and BMI usu-
ally decrease over time, because disease progresses. Therefore,
the clinical parameters (such as lung function) of 2011 are likely
to be worse for the cases with Scedosporium spp. and Exophiala
dermatitidis identified in 2010, than they actually were in 2010,
so the impact of a positive sputum culture could be overestimated
in these patients. Only three new cases with Scedosporium spp.
were identified in 2013, so this will have had little impact. De-
tection bias may have occurred in sicker patients who had more
respiratory tract cultures per quarter compared to other patients.
Increased respiratory sampling in this group may have led to a
higher fungal yield, providing an overestimation of the associa-
tion between decreased lung function and filamentous fungi. We
aimed to correct for differences in the number of (outpatient)
clinic visits by analysing unique patients instead of analysing the
number of sputum samples. Finally, it could be that the number
of patients with Scedosporium spp. or Exophiala dermatitidis
was not big enough to show slight differences.
In clinical practice, although there was no association
with FEV1 and BMI, Scedosporium spp. or Exophiala der-
matitidis may still be important at an individual level. For
example, Scedosporium apiospermum, Scedosporium prolifi-
cans, and Scedosporium auranticum were suggested as emerg-
ing pathogens among immuno-compromised patients and in
immuno-competent patients with a chronic lung disease.11,27,28
It has also been suggested that the presence of Scedosporium
apiospermum in the respiratory tract is clinically relevant be-
cause it may trigger an inflammatory response that can man-
ifest as an allergic bronchopulmonary disease.9 Furthermore,
Scedosporium species are reportedly difficult to treat because of
their resistance to antifungal agents, with Scedosporium prolifi-
cans being the most resistant.22,29 However, since the prevalence
of filamentous fungi is very high among patients with CF and
resistance is a serious problem, it becomes increasingly impor-
tant to identify the individual patient who requires antifungal
treatment.13 A careful selection of patients is necessary to avoid
unintentional selection of more viable but resistant fungi in the
respiratory system.30 We believe that watchful waiting in the
case of positive cultures with Scedosporium spp. and Exophiala
dermatitidis in CF is warranted because starting, switching, and
stopping azole therapy has the potential risk of selecting for re-
sistant fungal species with wild-type fitness.30
Our study showed that CF patients with and without Sce-
dosporium spp. or Exophiala dermatitidis were comparable in
terms of clinical parameters, that is, BMI and lung function, sug-
gesting that Scedosporium spp. and Exophiala dermatitidis are
probably no major pathogens for CF patients on a population
level. These findings should be confirmed in a larger study.
As the prevalence of filamentous fungi in the sputum of pa-
tients with CF is very high, greater understanding of epidemio-
logic trends, risk factors, and pathogenicity of filamentous fungi
in the respiratory tracts of patients with CF is needed to develop
evidence based management guidelines. This study suggests that
in general, it seems wise to withhold antifungal treatment when
encountering Scedosporium spp. or Exophiala dermatitidis in
patients with CF.
Supplementary material
Supplementary data are available at MMYCOL online.
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